Today we announced top-line results from our Phase 3, LYNX-2 Trial in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions. Read for more information here: bit.ly/3Hgf1w7

Today we announced positive top-line results from our second pivotal Phase 3 VEGA-3 Trial in presbyopia. Read for more information here: viatr.is/4k6uQTx

Today we provided an update on the Phase 3 Study of MR-139 for Blepharitis. Read more information here: viatr.is/4nWJUGB

We are celebrating a big win by #TeamCongress at last week’s CWSoftballGame! In addition to bringing together bipartisan lawmakers and members of the press corps, this game supports Young Survival Coalition in its mission to address the unique needs of young adults affected by breast cancer.

Today we announced that five abstracts from our Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference. Learn more: viatr.is/4fj8X2O

$VTRS reports second quarter 2025 results and reiterates 2025 financial guidance. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. viatr.is/4liY42q

Today we announced the FDA approval of the first generic iron replacement product to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD),helping facilitate increased access to this complex injectable product. Information here: viatr.is/3HqqpG1

We are here in Madrid at the #ESCCongress. Visit us at booth A200 to learn more about our efforts in reducing the burden of cardiovascular diseases and the latest on the SOS-AMI trial. #ESCCongress #WCCardio

Visit booth A200 at the #ESCCongress in Madrid to watch the premiere of a film we created with BBC StoryWorks dedicated to raising awareness on the importance of early detection of heart attack symptoms. Look for the full video later this month. #ESCCongress #WCCardio

Our team is on site at #PAINWeek2025, stop by to learn more about our efforts in addressing acute and chronic pain, and our Phase 3 program evaluating our investigational asset in moderate-to-severe acute surgical pain models. Read to learn more: viatr.is/3HKVVyL

This week we join global experts at #APLAR2025 to advance care for people with systemic lupus erythematosus (SLE), where our team will present insights from the Phase 2 CARE study—underscoring our commitment to addressing unmet medical need in SLE.

At #PAINWeek2025, we presented 5 abstracts from our Phase 3 program evaluating our investigational asset in moderate-to-severe acute surgical pain models, which further highlighted positive results from two previously announced Phase 3 studies. Learn more: viatr.is/4nh4KPS

We have been named to Forbes’ list of the World’s Best Employers for the 5th year in a row! Learn more about our culture that prioritizes wellbeing, promotes inclusivity, offers training, learning and development opportunities, and enables high performance viatris.com/careers

At the #AAOpt Congress, results from our Phase 3 LYNX-2 trial were presented highlighting our investigational asset being evaluated in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions. Read more: viatr.is/4oidS7h

$VTRS completes acquisition of Aculys Pharma including exclusive rights to pitolisant in Japan and to Spydia® in Japan and certain other markets in the Asia-Pacific region. Read more: viatr.is/46Uo68e

We are in Chicago at #ACRConvergence2025! Visit our team onsite to learn more about our efforts in systemic lupus erythematosus research, including OPUS, our ongoing global Phase 3 clinical trial program.

Today we reported third quarter 2025 results and updated our 2025 financial guidance. $VTRS Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. newsroom.viatris.com/2025-11-06-Via…

Recently, our team attended #AHA25 Scientific Sessions. Through our interactive booth and live discussions, we were able to share information about our SOS-AMI trial and overall progress in advancing solutions to improve cardiovascular health for patients worldwide.

We’re proud to share that Viatris has been named to the Fortune World’s Best Workplaces 2025—recognized among just 25 global companies! Learn more about our culture that supports wellbeing and embraces the diverse perspectives of our colleagues worldwide. viatris.com/careers

Today we announced four regulatory milestones spanning all stages of our global pipeline, culminating a year of significant R&D advancement. Read for more information here: newsroom.viatris.com/2025-12-18-Via…